Current Therapeutic Research-clinical and Experimental最新文献

筛选
英文 中文
Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Patients With Dry Eye Disease With Perfluorohexyloctane 研究全氟己基辛烷减轻干眼症患者眼睑拭泪器表皮病变症状的效果
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100786
Chris Lievens OD, MS, PhD, FNAP, FAAO , Andrew D. Pucker OD, PhD, FAAO , Quentin Franklin BS , Stephen M. Montaquila OD, FAAO , Brad Giedd OD, MS, FAAO , Gina Wesley OD, MS, FAAO , Morgan Bromley PhD , Zackarias Coker MS , John Meyers MS , Marta Vianya-Estopa PhD
{"title":"Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Patients With Dry Eye Disease With Perfluorohexyloctane","authors":"Chris Lievens OD, MS, PhD, FNAP, FAAO ,&nbsp;Andrew D. Pucker OD, PhD, FAAO ,&nbsp;Quentin Franklin BS ,&nbsp;Stephen M. Montaquila OD, FAAO ,&nbsp;Brad Giedd OD, MS, FAAO ,&nbsp;Gina Wesley OD, MS, FAAO ,&nbsp;Morgan Bromley PhD ,&nbsp;Zackarias Coker MS ,&nbsp;John Meyers MS ,&nbsp;Marta Vianya-Estopa PhD","doi":"10.1016/j.curtheres.2025.100786","DOIUrl":"10.1016/j.curtheres.2025.100786","url":null,"abstract":"<div><h3>Background</h3><div>Perfluorohexyloctane (PFHO) acts to prevent the evaporation of the tear film. It has the potential to limit friction related issues between the eye lid margin and the ocular surface. Prior to the present work, this had not yet been evaluated.</div></div><div><h3>Objective</h3><div>To examine the potential of using perfluorohexyloctane for reducing the signs and symptoms of lid wiper epitheliopathy (LWE).</div></div><div><h3>Methods</h3><div>Data were collected at 4 visits spanning 2 months. Patients who had symptomatic dry eye and a LWE score of ≥1.0 on the Korb LWE scale were recruited. Participants were randomized to PFHO 4 times a day or no treatment. Lid wiper epitheliopathy was graded at each visit with the Korb and photographic LWE (PLWE) scales. Symptoms were assessed using the Standard Patient Evaluation of Eye Dryness questionnaire and visual analog scales (0–100).</div></div><div><h3>Results</h3><div>A total of 52 participants were enrolled (mean ± SD age, 49.7 ± 15.7 years; 79% female). Right eyes in the treatment group were significantly more likely to show an improvement of ≥0.5-units in PLWE scores at 2 months than the no treatment group (<em>P</em> = 0.04), but no left eye differences were noted. Korb and PLWE scores were significantly better in the treatment group compared with the no treatment group starting at 2 weeks and remained so for the duration of the study (all <em>P</em> &lt; 0.001). Standard Patient Evaluation of Eye Dryness scores and dry eye symptoms were significantly better in the treatment than in the no treatment group at the 2-month visit (all <em>P</em> ≤ 0.01).</div></div><div><h3>Conclusions</h3><div>Perfluorohexyloctane significantly reduced LWE and improved dry eye symptoms compared with no treatment, suggesting that PFHO may enhance ocular lubrication and reduce friction-related damage. Masked, randomized, trials are still needed to compare PFHO to other treatments in participants with LWE to support generalizability of results. ClinicalTrials.gov study NCT06671041.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100786"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking the Value of Neuropsychological Assessments in Rehabilitation: Perspectives from Persons with Dementia and Their Caregivers 释放神经心理学评估在康复中的价值:来自痴呆症患者及其照顾者的观点
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100781
Takako Yoshimura , Aiko Osawa , Shiinchiro Maeshima , Iikue Ueda , Koki Kawamura , Masaki Kamiya , Naoki Itoh , Hidenori Arai
{"title":"Unlocking the Value of Neuropsychological Assessments in Rehabilitation: Perspectives from Persons with Dementia and Their Caregivers","authors":"Takako Yoshimura ,&nbsp;Aiko Osawa ,&nbsp;Shiinchiro Maeshima ,&nbsp;Iikue Ueda ,&nbsp;Koki Kawamura ,&nbsp;Masaki Kamiya ,&nbsp;Naoki Itoh ,&nbsp;Hidenori Arai","doi":"10.1016/j.curtheres.2025.100781","DOIUrl":"10.1016/j.curtheres.2025.100781","url":null,"abstract":"<div><h3>Purpose</h3><div>Various neuropsychological or cognitive assessments are often conducted before rehabilitation to ascertain patients’ function, disability, and environment. However, adequate assessments are not conducted for persons with dementia under the assumption that assessments would burden them. Therefore, this study investigated the perceptions of persons with dementia and their family caregivers regarding cognitive function assessments during hospital rehabilitation and reconsidered the significance of such assessments according to the opinions of those involved.</div></div><div><h3>Methods</h3><div>This cross-sectional observational study was conducted over a 3-month period at a hospital-based rehabilitation center. We administered a semi-structured questionnaire to 31 older persons with dementia (13 men and 18 women; mean age [± SD]: 77 [± 5.7] (range: 66–87 years); mean years of education [± SD]: 12 [± 2.3]; (range: 9–16 years); Alzheimer's disease: 15; mild cognitive impairment (MCI): 15; corticobasal degeneration: 1) and 49 family caregiver dyads (24 men and 25 women, mean age [± SD]: 67 [± 11] years; age range: 46–90 years). The data were interpreted by employing descriptive statistics, and the χ<sup>2</sup>, Fisher's exact, and Kruskal–Wallis tests.</div></div><div><h3>Findings</h3><div>Both groups acknowledged the value of neuropsychological assessments, with 94% (95% CI 84.9–100%) of persons with MCI/dementia and 83% (95% CI 73.3–94.0%) of their family caregivers linking them directly to enhanced treatment and care quality. Their positive attitudes were significantly associated with the belief that such evaluations are integral for personalizing and optimizing rehabilitation strategies.</div></div><div><h3>Implications</h3><div>Most individuals with MCI/dementia and their caregivers value detailed neuropsychological assessments for understanding rehabilitation needs, highlighting the importance of integrating comprehensive evaluations into dementia care. However, the single-center nature of our study limits generalizability. Future research with diverse participants is needed to develop scalable, inclusive rehabilitation strategies.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100781"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143684680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversing Morphine Induced Tolerance: Insights Into Cetirizine and Green Tea Extract Efficacy 逆转吗啡诱导的耐受性:西替利嗪和绿茶提取物疗效的见解
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100783
Tahereh Eteraf-Oskouei Phd , Adel Mahmoudi Gharehbaba Phd , Solmaz Asnaashari Phd , Zahra Fazli Phd , Bohloul Habibi Asl Phd
{"title":"Reversing Morphine Induced Tolerance: Insights Into Cetirizine and Green Tea Extract Efficacy","authors":"Tahereh Eteraf-Oskouei Phd ,&nbsp;Adel Mahmoudi Gharehbaba Phd ,&nbsp;Solmaz Asnaashari Phd ,&nbsp;Zahra Fazli Phd ,&nbsp;Bohloul Habibi Asl Phd","doi":"10.1016/j.curtheres.2025.100783","DOIUrl":"10.1016/j.curtheres.2025.100783","url":null,"abstract":"<div><h3>Background</h3><div>The treatment of chronic pain presents a considerable difficulty, particularly due to opioid dependence, which is marked by tolerance and withdrawal symptoms. Opioids primarily target mu (μ) opioid receptors, providing pain relief while also leading to various side effects. This research aimed to examine the effectiveness of cetirizine and green tea hydroalcoholic extract (EXT) in altering morphine tolerance and improving analgesic effects.</div></div><div><h3>Methods</h3><div>Adult male mice were divided into nine groups. In order to investigate the analgesic tolerance, animals received morphine on 14 consecutive days. Cetirizine (5, 10, 20 mg/kg, i.p.) and EXT (50, 100, 200 mg/kg, i.p.) were given before a test dose of morphine (9 mg/kg, i.p.). The analgesic effects were evaluated by the hot plate test.</div></div><div><h3>Results</h3><div>Cetirizine with doses of 5, 10, 20 mg/kg, and 10 mg/kg showed a significant effect in reducing morphine tolerance 30 min (<em>P</em> &lt; 0.0001) and 45 to 60 min (<em>P</em> &lt; 0.0001) after test dose of morphine (9 mg/kg, i.p.) respectively. While the injection of different doses of the extract did not show any effect on tolerance to morphine. In the combined injection of these two drugs, there was no reduction in tolerance to morphine.</div></div><div><h3>Conclusions</h3><div>Cetirizine but not EXT reversed morphine tolerance. Furthermore, the co-administration of cetirizine and EXT did not yield any significant benefits compared to the individual treatments.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100783"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unleashing the Potential of Givinostat: A Novel Therapy for Duchenne Muscular Dystrophy 释放吉维司他的潜能:一种治疗杜氏肌营养不良症的新疗法
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100787
Ahmad Furqan Anjum MBBS, BSc , Muhammad Burhan Anjum MBBS , Raza ur Rehman MBBS, Bsc
{"title":"Unleashing the Potential of Givinostat: A Novel Therapy for Duchenne Muscular Dystrophy","authors":"Ahmad Furqan Anjum MBBS, BSc ,&nbsp;Muhammad Burhan Anjum MBBS ,&nbsp;Raza ur Rehman MBBS, Bsc","doi":"10.1016/j.curtheres.2025.100787","DOIUrl":"10.1016/j.curtheres.2025.100787","url":null,"abstract":"<div><h3>Purpose</h3><div>Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder with limited treatment options beyond corticosteroids, which have significant adverse effects. Givinostat, a histone deacetylase inhibitor, has recently emerged as a promising disease-modifying therapy. This commentary examines the therapeutic potential of givinostat, its mechanism of action, and the clinical evidence supporting its role in DMD treatment.</div></div><div><h3>Methods</h3><div>A review of the EPIDYS Phase 3 trial and supporting clinical studies was conducted. The study included boys aged 6 to 17 years with genetically confirmed DMD, assessing givinostat's efficacy and safety over 18 months. Key endpoints included the North Star Ambulatory Assessment (NSAA), MRI-based muscle preservation, and adverse event (AE) profiles.</div></div><div><h3>Findings</h3><div>Givinostat-treated patients demonstrated a 1.9-point higher NSAA score compared to placebo (<em>P</em> = 0.03), with significant reductions in muscle fat infiltration (40% lower than placebo; <em>P</em> &lt; 0.05). Functional tests showed trends toward improved stair-climbing ability, though not statistically significant. AEs included thrombocytopenia (20%) and hypertriglyceridemia (10%), necessitating monitoring but remaining manageable.</div></div><div><h3>Implications</h3><div>Givinostat represents a paradigm shift in DMD management, offering benefits beyond corticosteroids by reducing fibrosis and promoting muscle regeneration. While its long-term safety and cost-effectiveness require further evaluation, its combination potential with gene therapies highlights its importance in future DMD treatment strategies. Ongoing studies aim to refine its role in broader neuromuscular disorders.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100787"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nano-Amounts of Glucagon Premixed With Fast-Acting Insulin Lispro: Effect on Insulin Absorption in Pigs 纳米级胰高血糖素与速效胰岛素利斯普罗预混:对猪胰岛素吸收的影响
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100803
Ilze Dirnena-Fusini PhD , Misbah Riaz MSc , Sverre Christian Christiansen MD, PhD , Sven Magnus Carlsen MD, PhD
{"title":"Nano-Amounts of Glucagon Premixed With Fast-Acting Insulin Lispro: Effect on Insulin Absorption in Pigs","authors":"Ilze Dirnena-Fusini PhD ,&nbsp;Misbah Riaz MSc ,&nbsp;Sverre Christian Christiansen MD, PhD ,&nbsp;Sven Magnus Carlsen MD, PhD","doi":"10.1016/j.curtheres.2025.100803","DOIUrl":"10.1016/j.curtheres.2025.100803","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon leads to substantial but short-lived subcutaneous vasodilation. Using micro-amounts of glucagon at the insulin injection site increases insulin absorption.</div></div><div><h3>Objective</h3><div>We hypothesized that a premixed solution of insulin and nanogram doses of glucagon would improve the pharmacokinetic and pharmacodynamic properties of subcutaneously injected insulin.</div></div><div><h3>Methods</h3><div>In this series of proof-of-concept experiments, 17 anesthetized pigs were included. Nine pigs were included in the control groups; they received a subcutaneous injection of 10 U of insulin lispro (Lyumjev<sup>Ⓡ</sup> or Humalog<sup>Ⓡ</sup>). Eight pigs were included in the glucagon groups; they received 10 U of a premixed insulin (Lyumjev<sup>Ⓡ</sup> or Humalog<sup>Ⓡ</sup>)/glucagon solution (5 ng glucagon/unit of insulin). Arterial blood was frequently sampled for 210 minutes to assess insulin and glucose concentrations. The impact on glucose metabolism was evaluated through euglycemic clamp investigation.</div></div><div><h3>Results</h3><div>When premixed insulin Lyumjev<sup>Ⓡ</sup>/glucagon was injected, insulin T<sub>max</sub> decreased from 33 to 20 minutes (SE = 6.6, <em>P</em> = 0.08), and C<sub>max</sub> was 2-fold higher than that in the control group (100 mU/L vs 46 mU/L, SE = 4.8, <em>P</em> = 0.007). When premixed insulin Humalog<sup>Ⓡ</sup>/glucagon was injected, T<sub>max</sub> and C<sub>max</sub> did not change significantly (<em>P</em> = 0.53 and <em>P</em> = 0.83, respectively). Insulin AUC for the first 15 minutes increased two-fold when insulin Lyumjev<sup>Ⓡ</sup>/glucagon was injected (946 mU×min/L vs 337 mU×min/L, SE = 196, <em>P</em> = 0.02). A similar trend was observed when Humalog<sup>Ⓡ</sup>/glucagon was injected (306 mU×min/L vs 65 mU×min/L, SE = 125), although this difference did not reach statistical significance (<em>P</em> = 0.102) compared with the control groups.</div></div><div><h3>Conclusions</h3><div>This series of proof-of-concept experiments in anesthetized pigs indicate that premixing nanogram doses of glucagon in fast-acting insulin lispro formulations may speed up the absorption of subcutaneously injected insulin.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100803"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial 二肽基肽酶-4抑制剂对2型糖尿病合并非酒精性脂肪肝患者转氨酶水平的影响:一项随机对照试验的荟萃分析
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2024.100768
Gang Ma MD , Song Zhang MD , Baozhong Yu MD
{"title":"Impact of Dipeptidyl Peptidase-4 Inhibitors on Aminotransferases Levels in Patients with Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trial","authors":"Gang Ma MD ,&nbsp;Song Zhang MD ,&nbsp;Baozhong Yu MD","doi":"10.1016/j.curtheres.2024.100768","DOIUrl":"10.1016/j.curtheres.2024.100768","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent diseases that constitute enormous public health problems. The efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors in blood glucose control in T2DM patients with NAFLD has been established, but little is known about its effect on liver enzyme levels.</div></div><div><h3>Objective</h3><div>This meta-analysis aimed to evaluate the influences of DPP-4 inhibitors on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2DM and NAFLD.</div></div><div><h3>Methods</h3><div>To identify the relevant studies, we searched PubMed, Embase, the Cochrane Library, Wanfang Data, and China National Knowledge Infrastructure. Means differences in liver enzymes and metabolic outcomes were meta-analyzed using a random-effects model, with subgroup analyses by gender, age, area, follow-up duration, and type of DPP-4 inhibitor. Quality assessment of the included studies was conducted using the revised Cochrane risk of bias tool.</div></div><div><h3>Results</h3><div>A total of 1323 patients from 16 studies were included in this meta-analysis. The results of analysis of DPP-4 inhibitors showed that the mean difference was –6.19 (95% confidence interval [CI]: –9.45 to –2.92) for ALT and –5.17 (95% CI: –8.10 to –2.23) for AST; this effect was statistically significant from the placebo group which indicates the beneficial effect on liver enzymes. Subgroup analysis revealed that while there were no significant gender differences in enzyme reductions, individuals over 55 years old experienced more pronounced decreases in ALT. Notably, Asian studies showed significant reductions in liver enzymes, contrasting with the minor variations observed in Euramerican regions, and the effectiveness of DPP-4 inhibitors was particularly pronounced during shorter follow-up periods, with effects diminishing over time. Regarding secondary outcomes, there was a notable improvement in gamma-glutamyl transpeptidase, with a mean reduction, and in HbA1c levels, indicating improved glycemic control. Homeostatic model assessment for insulin resistance levels also improved, reflecting better insulin sensitivity. Additionally, adverse event analysis confirmed that DPP-4 inhibitors were well-tolerated with a favorable safety profile.</div></div><div><h3>Conclusions</h3><div>DPP-4 inhibitors appear to enhance glycemic control and improve liver enzyme levels, suggesting a potentially effective therapeutic approach for managing T2DM/NAFLD and highlighting their broader metabolic benefits.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100768"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Side Effect of Different Doses of Glucocorticoids on Sudden Deafness 不同剂量糖皮质激素治疗突发性耳聋的疗效及不良反应
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100794
Ya He M.D. , Liang’e Zhi M.Med , Yajin Feng B.Med , Shiyuan Li B.Med , Qian Liu B.Med , Zhendong Jiang M.D. , Cheng Zhong M.D.
{"title":"Efficacy and Side Effect of Different Doses of Glucocorticoids on Sudden Deafness","authors":"Ya He M.D. ,&nbsp;Liang’e Zhi M.Med ,&nbsp;Yajin Feng B.Med ,&nbsp;Shiyuan Li B.Med ,&nbsp;Qian Liu B.Med ,&nbsp;Zhendong Jiang M.D. ,&nbsp;Cheng Zhong M.D.","doi":"10.1016/j.curtheres.2025.100794","DOIUrl":"10.1016/j.curtheres.2025.100794","url":null,"abstract":"<div><h3>Background</h3><div>Sudden deafness (SD) presents as rapid-onset sensorineural hearing loss within 72 hours, with unknown etiology. Current guidelines recommend systemic corticosteroids as first-line therapy, though high-dose regimens may increase risks of hypertension and hyperglycemia. No consensus exists on optimal SD treatment protocols.</div></div><div><h3>Objective</h3><div>To compare the treatment efficacy and side effects of different doses of glucocorticoids in patients with sudden deafness.</div></div><div><h3>Methods</h3><div>A total of 248 patients (from July 2020 to May 2022) with sudden deafness were divided into 3 groups based on their initial dexamethasone dosages: group A (adequate dose, 10 mg/d), group B (high dose, 15 mg/d), and group C (high dose, 20 mg/d). For treatment efficacy, the mean hearing threshold elevation was subsequently evaluated. For side effects, blood glucose and blood pressure were monitored in 14 patients with sudden deafness accompanied by diabetes and 20 patients with concomitant primary hypertension.</div></div><div><h3>Results</h3><div>There was no significant difference in the efficacy of various initial corticosteroid doses among different subgroups (all <em>P</em> &gt; 0.05). Higher initial doses were associated with increased risk of rapid glucose in patients with diabetes, whereas no significant difference was observed in blood pressure fluctuation among the 3 groups.</div></div><div><h3>Conclusions</h3><div>The treatment efficacy of the 3 different corticosteroid doses in sudden deafness treatment was comparable; yet, an increased risk of rapid blood glucose increase was accompanied by the elevated dose of dexamethasone in patients with diabetes. Therefore, an adequate glucocorticoid (dexamethasone, 10 mg/d) could be the optimal regimen of patients with sudden deafness and diabetes.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100794"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144130856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System 钾竞争性酸阻滞剂与质子泵抑制剂对胃溃疡的疗效:通过质量管理体系交叉推断的贝叶斯和频率网络meta分析
IF 1.6
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100776
In Mo Yoon MD, PhD , Kang-Yon Kim MD , Kwan-Haeng Lee MD , Duk-Woo Yoo DMD , Hojin Oh PharmD
{"title":"Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System","authors":"In Mo Yoon MD, PhD ,&nbsp;Kang-Yon Kim MD ,&nbsp;Kwan-Haeng Lee MD ,&nbsp;Duk-Woo Yoo DMD ,&nbsp;Hojin Oh PharmD","doi":"10.1016/j.curtheres.2025.100776","DOIUrl":"10.1016/j.curtheres.2025.100776","url":null,"abstract":"<div><h3>Purpose</h3><div>Proton pump inhibitors (PPIs) have been the mainstay treatment for gastric ulcer (GU) for over 30 years. However, since the discovery of a new class of acid suppressants, potassium-competitive acid blockers (P-CABs), the desire for a therapeutic agent has continued and the clinical trials on P-CABs have been conducted. In this regard, we aimed to assess whether P-CABs are noninferior to PPIs in patients with GU in terms of efficacy.</div></div><div><h3>Methods</h3><div>We performed a systematic review and network meta-analysis (NMA) based on randomized controlled trials (RCTs). Additionally, we used a new methodology of inference concept with the purpose of grouping between P-CABs and PPIs. Moreover, our quality management system was integrated throughout the research to ensure data accuracy.</div></div><div><h3>Findings</h3><div>We initially screened 438 studies and extracted 10 homogeneous GU RCTs with 6315 participants. The odds ratios (ORs) for the 4-week cure rate in Bayesian + frequentist NMA, tegoprazan 100 mg (OR = 4.14, 95% credible interval [CI] 0.56–26.3) and pantoprazole 40 mg (OR = 4.12, 95% CI 1.90–8.88) were the largest, respectively. The ORs for the 8-week cure rate in Bayesian + frequentist NMA, lansoprazole 30 mg (OR = 8.77, 95% credible interval [CI] 0.95–78.9) and lansoprazole 30 mg (OR = 7.91, 95% CI 2.60–24.03) was the largest, respectively.</div></div><div><h3>Conclusions</h3><div>The results of the NMA reveal that the cure rates of P-CABs in cases of GU were not inferior to those of PPIs. As the inference by grouping PPIs and P-CABs, the results showed similar trends in terms of effectiveness between the two therapeutic classes.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100776"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143509093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends 沙特阿拉伯NGHA医疗保健系统中2型糖尿病药物的启动:当代趋势
IF 1.5
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100809
Mesnad S. Alyabsi PhD , Lolwah Almousa BS , Anwar H. Alqarni BS , Asma Aldawsari MS , Lubna Alnasser PhD , Adel F. Almutairi PhD
{"title":"Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends","authors":"Mesnad S. Alyabsi PhD ,&nbsp;Lolwah Almousa BS ,&nbsp;Anwar H. Alqarni BS ,&nbsp;Asma Aldawsari MS ,&nbsp;Lubna Alnasser PhD ,&nbsp;Adel F. Almutairi PhD","doi":"10.1016/j.curtheres.2025.100809","DOIUrl":"10.1016/j.curtheres.2025.100809","url":null,"abstract":"<div><h3>Background</h3><div>Continuous updates in management guidelines for type 2 diabetes mellitus (T2DM) have affected treatment patterns. In this study, we aimed to identify the prevalence of initiating various antidiabetic medications and analyze differences in patient characteristics based on the type of treatment initiated.</div></div><div><h3>Methods</h3><div>This cross-sectional study used data retrieved from the electronic medical records of the National Guard Health Affairs for all patients diagnosed with T2DM who initiated any antidiabetic therapy between January 2018 and May 2022. Patient data were presented using frequencies, percentages, means, and standard deviations where applicable. The antidiabetic classes investigated include metformin, insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter-2 inhibitors.</div></div><div><h3>Results</h3><div>In total, 433 patients with T2DM were included in this study, most of whom were females (55.66% vs 44.34%) and obese (61.20%), with a mean age of 53.29 years (SD ± 15.22). Monotherapy was the most commonly initiated approach (66.28%), with insulin being the most prescribed monotherapy (29.10%). The most frequent combination therapy was metformin and sulfonylureas (7.16%). Overall, the most initiated medication was metformin, accounting for 37.12% of all prescriptions. Additionally, there was an increasing trend in prescribing newer medications, such as GLP-1 receptor agonists (8.70%) and SGLT-2 inhibitors (11.11%), for newly diagnosed patients in 2021.</div></div><div><h3>Conclusion</h3><div>The initiation of novel antidiabetic medications has increased over the study period, reflecting recent updates in T2DM management guidelines. However, further understanding of their benefits is required for optimal patient care.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100809"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Intravenous Lidocaine on Postoperative Cognitive Dysfunction in Patients Undergoing Laparoscopic Colorectal Surgery: A Two-Center, Randomized, Double-Blind Controlled Trial 静脉注射利多卡因对腹腔镜结直肠手术患者术后认知功能障碍的影响:一项双中心、随机、双盲对照试验
IF 1.5
Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI: 10.1016/j.curtheres.2025.100808
Ke-peng Liu , Jing Dai , Fu-rong Huang , Hui-wei Deng , Qi Wang , Yun Liu , Yong Chen , Lilong Mo , Fangni Cao , Yan Zhang , Hua-jing Guo , Xian-xue Wang
{"title":"Effect of Intravenous Lidocaine on Postoperative Cognitive Dysfunction in Patients Undergoing Laparoscopic Colorectal Surgery: A Two-Center, Randomized, Double-Blind Controlled Trial","authors":"Ke-peng Liu ,&nbsp;Jing Dai ,&nbsp;Fu-rong Huang ,&nbsp;Hui-wei Deng ,&nbsp;Qi Wang ,&nbsp;Yun Liu ,&nbsp;Yong Chen ,&nbsp;Lilong Mo ,&nbsp;Fangni Cao ,&nbsp;Yan Zhang ,&nbsp;Hua-jing Guo ,&nbsp;Xian-xue Wang","doi":"10.1016/j.curtheres.2025.100808","DOIUrl":"10.1016/j.curtheres.2025.100808","url":null,"abstract":"<div><h3>Background</h3><div>In patients undergoing gastrointestinal surgery, enhancing perioperative cognitive function and facilitating expedited postoperative recovery are critical components for achieving swift rehabilitation. Intravenous administration of lidocaine has been shown to mitigate the perioperative inflammatory response in surgical patients; however, its influence on postoperative cognitive performance remains unassessed. Consequently, this study was conducted to investigate the impact of intravenous lidocaine on postoperative cognitive function in participants undergoing laparoscopic surgery for colorectal cancer.</div></div><div><h3>Methods</h3><div>We performed a prospective, randomized controlled trial at The First People’s Hospital of Changde City and Zhongshan People’s Hospital to assess the impact of intravenous lidocaine on postoperative cognitive dysfunction (POCD) in patients undergoing laparoscopic radical resection for colorectal carcinoma. The primary endpoints of our investigation included Mini-Mental State Examination (MMSE) scores measured preoperatively and 7 days postoperatively, as well as the incidence of POCD at the 7-day mark following surgery. Secondary outcomes comprised an evaluation of recovery parameters in the postanesthesia care unit, overall length of hospitalization, and the prevalence of postoperative complications in both study cohorts.</div></div><div><h3>Results</h3><div>The occurrence of POCD at day 7 postsurgery was significantly lower in the lidocaine group compared to the placebo group (<em>P</em> &lt; 0.05). When stratified by age, both elderly patients (≥65 years) and nonelderly patients in the lidocaine group exhibited a significantly reduced incidence of POCD on the seventh day postoperatively compared to the placebo group (<em>P</em> &lt; 0.05). Preoperative MMSE scores were comparable between the two groups; however, on the seventh day after surgery, the lidocaine group had significantly higher MMSE scores than the placebo group (<em>P</em> &lt; 0.05). In the nonelderly cohort, MMSE scores were also significantly elevated in the lidocaine group compared to the placebo group at day 7 postsurgery (<em>P</em> &lt; 0.05). Mediation analysis indicated that lidocaine’s influence on the incidence of POCD on the seventh postoperative day was partially mediated by propofol. Furthermore, there were no significant differences observed in intraoperative medication, postoperative recovery, or perioperative adverse events between the groups (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusions</h3><div>Perioperative administration of intravenous lidocaine has been shown to significantly enhance cognitive function on the seventh postoperative day following laparoscopic colorectal surgery. The mediating influence of propofol on the association between lidocaine and the occurrence of POCD at this time point was determined to be 10%.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100808"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144866119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信